Randomized Trialhigh evidence
Neurokinin pathway botanical antagonist for menopausal vasomotor symptoms: A randomized, double-blind, placebo-controlled study.
Maturitas·June 10, 2026·PMID 42284819
Why it mattersFor clinicians managing menopause, this study offers evidence for a nonhormonal, botanically derived option targeting neurokinin pathways, which may appeal to patients seeking alternatives to hormone therapy. The significant reduction in vasomotor symptoms and daily interference supports its potential role in symptom management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled